{"name":"Ophthalmology Consultants, Ltd.","slug":"ophthalmology-consultants-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"vigamox","genericName":"vigamox","slug":"vigamox","indication":"Other","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"besivance","genericName":"besivance","slug":"besivance","indication":"Bacterial conjunctivitis","status":"marketed"}]}],"pipeline":[{"name":"vigamox","genericName":"vigamox","slug":"vigamox","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"besivance","genericName":"besivance","slug":"besivance","phase":"marketed","mechanism":"DNA gyrase, Topoisomerase IV","indications":["Bacterial conjunctivitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPYkFkcnZPbVI5UmZYSzg5S1RlbUE0UjZKVkNlVTlab1NJR2gxdjRxVG9uM1VlOURjcDFmSWhxalFmLVM4ZVBoWUNkZXVWZjRGdkNtRldlVV9JbUNXQ29GcXpGemZER3JZdURoWEVuamdMTVhHWWlTQVpyMzJIOUpBMGlURUxzYmdLMlVUa1NlLW4tUmZQOERyY3RmSWVTMEtfTXJYaVRuYXliWXIxdnFPMm50Y1ZiN2ZETVE?oc=5","date":"2026-02-27","type":"pipeline","source":"Eyes On Eyecare","summary":"Case reports indicate positive outcomes of CAM for OSD management - Eyes On Eyecare","headline":"Case reports indicate positive outcomes of CAM for OSD management","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxNTkdScVptYklQRW1ZTXdrb29sRFVZS3l1N2xRWlFmR3JXWXM5Y2xnd3NjdFVJTlc4emVxcXlBYTIwRnFPVHJJbWI0X3VHQ1FFVGVXQkJIU3dDVTM5Uy1RVHljZDd2T0MxSnZBZDItWVhnQS1IeDAxUGF5Q09uNmhJOHRpR3pEcVA5U1dxVEhOYmdEczJmbVk5andHZ2tfOGh6cjMyYlB1cklnaEc2UTVmRWJuZGpObG84dHZsbDZzSTJsa21EM24zSWhyRThFeUd4TVZCMHluLVhVNmZrSE9VczNMNXd5X0d3V3BUQzBORzI?oc=5","date":"2026-02-10","type":"pipeline","source":"BioSpace","summary":"OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer - BioSpace","headline":"OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Office","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1vTHFTYW13ZVA0M21hVFRXTFBJMEg3TUhXaDB6MWFvVlJucVpOMnNaWEZnWmt6bjlPZGNZVWNWR2tDUnhiZ1JQcWxjcDZhRXdTTGFGX3pFdU1WRnJnN2Zr?oc=5","date":"2025-12-05","type":"trial","source":"nature.com","summary":"Proportion of patients with Demodex blepharitis in ophthalmology clinics in Europe: the Eos study - nature.com","headline":"Proportion of patients with Demodex blepharitis in ophthalmology clinics in Europe: the Eos study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPM3ZpUnV0WEFzakkzQ3lHVXlhTFpzYkpOdEFmOGxGOU5UdjNNRVpfYUFEbHhCcXZhRGd3bFRXZWY5WDZVSTFiMklqTFdCY1R4ZnBLdlVBcTB1MFR4TnR4UHhJYXpzdkpTcDhia2wwS0QxS2FNeDNCS0RMOEV0a1V6T1lPbERqTnNWQW1MY194M1BMNHpIeW9BVTAzWWwyNDl1ck9hWA?oc=5","date":"2025-08-28","type":"pipeline","source":"Healio","summary":"Breakthrough therapies in dry eye limited by access - Healio","headline":"Breakthrough therapies in dry eye limited by access","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNT1NYbGFYdFYtQ0MwLV9tQ3FQODZHUHdWa2JKRy1FMVdfazdCQVR3VzdyWVlINEpGc2xCU0k0VVZGaXlsSnV6dFlTOHh6dnhRUlhfcXYyMEFWNXV5MUU1Uno0R0dsUV93Z0NmT2JSeU5pSl9pTk43cW1aTXNrR1lQQ3JQdmZOSUZDM1pXa3ljNWgxRWdy?oc=5","date":"2025-06-18","type":"pipeline","source":"MarketsandMarkets","summary":"Ophthalmology Drugs Market Report 2025-2030, By Molecule, Modality, and Geo - MarketsandMarkets","headline":"Ophthalmology Drugs Market Report 2025-2030, By Molecule, Modality, and Geo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPVGs2UnRaN0pWYmtHaDVSSFN3enFSQXFwUElCSU9nRDhVUktVcUlOSlFuTU9yNTdqeFpYRnpVUGJEaGItdk9HZmEwempWQjBYY3dJaGl5ck5PZFpaeHJQN1p1dGJ2SWtqZmN5QmxrX0pRNjhZbEhVeUhxT2VjbTVWcGxHald4ZUx5b25pajZOR3kxd3hIaXFpZzJPdzh2dw?oc=5","date":"2025-01-15","type":"regulatory","source":"Ophthalmology Advisor","summary":"FDA Alerts: Ophthalmology Drug and Device Approvals - Ophthalmology Advisor","headline":"FDA Alerts: Ophthalmology Drug and Device Approvals","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQQkNKRTdRVkRjM2t4dlV0ZXhkamV4S0xRdjIyaWNJeGNVQ2JSZzdHY2xDV2puVGVQWDZmc2lvOWpvemJaQWJIb0JfVzdCZlRjQlp0QlEtMk1XWTQxaGdRWXkyajNzN2FlLVpBc2Npd0VCRHlraE5BUE5jSTFhbktPaU5fNA?oc=5","date":"2024-11-05","type":"pipeline","source":"pharmaphorum","summary":"NICE backs first ophthalmic bevacizumab for NHS use - pharmaphorum","headline":"NICE backs first ophthalmic bevacizumab for NHS use","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPUVJFMTV4VU01S04wWmxNa1ZZU2RraW5ERWRkRldwdXJlRVlKeERvc2JRQnNKYUkxTWhuSjhXSGVXb3o3RGd5bVFuVnZ2WWZMLWpkZkQ1RlFlMVVUZTZpNnBfbS1jd0hfdFE4YWo3TUp2amJNR0x4YWJnMUtzcGx3d1JaVDlBcXd3ZDVIY0Q1TC1Qellrb0p5MWdkekdybGpJY0VWbDRnRjhnS1pfN0kzNU01M1o4ZlNSZDFvWHpTMmZMWWZXa3BsWTNnamI?oc=5","date":"2024-08-16","type":"pipeline","source":"dovepress.com","summary":"OPTH - dovepress.com","headline":"OPTH","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxNY0F6dWlrZk5DekFxRG15YnljVkV0QkV2N21pTlFkUUJtcWdwSjFpYTNFVHFlVzVBcTVjMTdZUzhfNTNLY3JNOW5LN0dnRWh4ZmZOeUROb2FuNUd2NVFqMXlmQnVlUWk4MzduQ3REbzFlQ0dzdXV0N3JZUHMyQnBJOFU4V2RlRzE3a25ldkc5TnljU0RsYVAwc2wzRVg4S2gwSEoyeUlHWUNoSDhMcVFWYTRPNHBnRDFpdEJOZHFRa3RXVWZoTGYxLWRyYWlCSDFKRTRBTGg1cHdMZ3llVzRvcXF1RmpUbVRpa1NXWmpMWnk5ajNvN0VHdXZCTXFzOTVQZlE3dVlKTVVVSk1RVG9oZ3hfd1JoMUttTG11YncxSXVvVzc0aF8xMTRobHdRVHZKM0NuRFZjbmpHLXEwdVhHMnk3dTdrLWEyMV92Tnp3?oc=5","date":"2024-02-19","type":"trial","source":"GlobeNewswire","summary":"Gene Therapies In Ophthalmology Clinical Trial Pipeline - GlobeNewswire","headline":"Gene Therapies In Ophthalmology Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBYS3N1UTdUZmplTVlabVNHXzdqUlFiX2ZxOVFKb0hlZldiWkZBRzFiOC03T2lpOXJxVFZNMF9oUlRTU2g1cURlM3FYMnVsZU1XRjlLemFTVHlDcnhmZENB?oc=5","date":"2024-02-05","type":"pipeline","source":"nature.com","summary":"The ophthalmologist’s guide to evaluating the certainty of evidence using the GRADE approach | Eye - nature.com","headline":"The ophthalmologist’s guide to evaluating the certainty of evidence using the GRADE approach | Eye","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AJBVV95cUxOSVRXMWpzcEJQdUI2V001dDk5V1NjTTY2blpMV2lZSjFHeFF2ZXEwWUVhZHZ1MHhCYi1SXzRoUlMzYjZvVDJIUGhhM0JHYXBkc3NsLVMxNlpYRXRHb2hkSFQtWkJMWWljWjM4MWlnLVRRWVZZa1IxN1lhX09FaExTbHpFZDZ3cEh3OGpvTUZ3WE5QVkpsYTA5SnpYODd2R2dLUm02dTViVnp0Qzg2clNqOGJzS1NQeU1MRnp0aUlua3lFVGRKY28wVzBQeC12MWdicDQ2SmxCSm81TmhDWm1VeEZ0alI3TnJDRGJfdUlSV2NHZjNpYnRCWnM0eDlOcHFyTGRsTGVoR0JNVVY2WERRTGEwdWlwenBwWXNBd3Z4UlY0Sy1EbGhiRkFsMFRQdzhiRWxqTlVkRHBmR19qZjVIMnRDWVZiaW0wWFRBendCQ0pBajd6UGM5dQ?oc=5","date":"2023-12-18","type":"pipeline","source":"Business Wire","summary":"Nordic Pharma Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Completes Acquisition of Visant Medical to Launch Novel Therapy for Dry Eye Disease in the United States - Business Wire","headline":"Nordic Pharma Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Completes Acquisition of Visant Medical to ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwJBVV95cUxObG9fNnFzOFBNRlBFbzBLdUtNOEh6Uzd1akZubExnUnQ1dkFwTnp5RDBmempjQkp4UGE3bGhJck5aTENVZUZ4QkxvQW44RGJnMVZEN3A4QTktOVoxeVNrSUhETkpnRVIxcElrZ3NhLU5nd1NpVlloVlNkVC1ENzhabnR2YlVxbWtQR2RqcWpOTWJKOXhmZTEwa19vNm9pd3FrdVZRS0JSYkJKNnQzX21fWG1PLV95UEN5TEJhQ3ZZZ1ExbGJLa1IzSWJaaTcwV280VmtyWHJ1UWlfclc1cEF3ajNiaGZnNjBpeU9qUVJMbnhzN2dRWkpXQTJnRWRZTmZEME9oSVktTVVaVmFabUUxYmRHVUl1STFBLU9fcFdHeGxoMUhxazdzZ2hxeG9OUlM4MUN6MnFEVFhydV9obzB3a25uQQ?oc=5","date":"2020-07-28","type":"pipeline","source":"PR Newswire","summary":"New Licensing Agreement Accelerates the Development of IACTA Pharmaceuticals' Novel Dry Eye Disease and Allergic Conjunctivitis Treatments in China and Southeast Asia - PR Newswire","headline":"New Licensing Agreement Accelerates the Development of IACTA Pharmaceuticals' Novel Dry Eye Disease and Allergic Conjunc","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}